Telix Pharmaceuticals names CEO of U.S. operations
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
Australia-based Telix Pharmaceuticals Limited has appointed Kevin Richardson as chief executive officer of Telix Americas in Fishers. The nuclear medicine company says Richardson most recently served as chief operating officer of UroShape Medical, a Florida-based company that developed medical devices.
Telix, which opened its U.S. headquarters in the Hamilton County city in 2020, also has operations in Belgium, Japan and Switzerland.
Telix says Richardson’s background includes 25 years of work in the healthcare industry, helping develop growth strategies to support new and emerging medical devices and therapies, including nuclear medicine. His career has focused on sales, marketing and business operations within the oncology and radiopharmaceutical sectors.
“Kevin brings a new depth of commercialization, sales and marketing experience to our U.S. operations along with a solid understanding of the intricacies of the radiopharmaceutical industry,” said Dr. Christian Behrenbruch, group CEO and managing director. “His experience will be extremely valuable as we maximize the opportunity of our first commercial product and as we prepare to bring additional products to market.”
Richardson previously spent seven years working in the America’s division of Sirtex Medical, an Australian-founded radiopharmaceutical company. Telix says he has also held senior sales roles with St. Jude Medical and Boston Scientific.
Earlier this year, Telix received approval from the U.S. Food and Drug Administration to launch its first commercial product, Illuccix, which uses Molecularly Targeted Radiation to identify the spread of cancer cells.